News

The soft tissue sarcoma trial was completed and provided evidence of clinical activity. The initial analysis of the results supports continued development of the compound for this indication

The 30 month results comprise the final timepoint for the now-completed Diamyd study. Positive results have previously been reported after 15 and 21 months. The Phase IIb study

The clinical studies evaluated the effect of the filter on units of red cell concentrate collected from human volunteers, to ensure that the use of the filter had

The therapeutic areas included in these awards are oncology, gynecology, respiratory diseases, and gastroenterology. Services to be provided include project management, field monitoring, data management, statistics, medical writing,

Onconase, a first-in-class product candidate from Alfacell’s proprietary ribonuclease (RNase) technology has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. Onconase,

With this agreement, Celsion will begin immediate implementation of the study which has been planned in detail during the course of FDA’s review. The study is designed to

The strategic alliance agreement is for five years between Azopharma and Accu-Break Pharmaceuticals (ABP). Azopharma will provide sales and marketing support for Accu-Break technologies for five years. The

The company has also granted the underwriters a 30-day option to purchase up to an additional 1.5 million shares of common stock to cover over-allotments, if any. All

A submission has already been sent to the Swedish Medicinal Products Agency. Additional submissions will be sent to other European countries. The study is proposed to include approximately